IASLC Leadership Shares Experiences, Offers Advice for Women in Thoracic Oncology
Erin JungmeyerDuring a networking panel at NACLC 22, CEO Karen Kelly and President Heather Wakelee joined program co-chairs Drs. Jessica Donington, Marina Chiara Garassino, and Jyoti Patel for a discussion with other women in the field. Read more
Upcoming IASLC meetings offer educational opportunities around the globe. Read more for registration and abstract news from LACLC, ACLC, and TTLC. Read more
NACLC 22 Educational Session Explores the Rationale for Immune Checkpoint Inhibition
Erin JungmeyerDuring IASLC’s North America Conference on Lung Cancer, MD Anderson’s Dr. Tina Cascone reviewed the evidence for neoadjuvant and adjuvant therapy in NSCLC. Read more
Researcher Reveals How Air Pollution May Cause Lung Cancer
Erin JungmeyerDuring ESMO Congress 2022, Prof. Charles Swanton shared data that show cells with EGFR and KRAS gene mutations can turn cancerous when exposed to pollution from the burning of fossil fuels. Read more
KEYNOTE-604 Follow-Up Results Continue to Show Clinically Meaningful Improvement
Cody HoltLong-term data presented by Dr. Charles Rudin during WCLC 2022 showed significant OS benefit for patients with extensive stage SCLC on pembrolizumab combination versus placebo. Read more
Study Shows Shorter-Term Assessments Underestimate Pollution Exposure
Cody HoltDuring WCLC 22, Dr. Renelle Myers demonstrated the importance of considering long-term cumulative exposure to air pollutants when assessing individual lung cancer risk. Read more
POSEIDON Analysis Shows Sustained Benefit with Triplet Regimen Regardless of Mutational Status
Cody HoltDr. Solange Peters showed 24-month overall survival rates were higher with tremelimumab, durvalumab, and chemotherapy versus chemotherapy alone across all subgroups, including those with KRAS, STK11, and KEAP1 mutations. Read more
In a Q&A with ILCN, Dr. Karen Kelly looks back at the moments that made lasting impressions and the presentations with the power to change the practice of thoracic oncology. Read more
Unclear Informed Consent Forms May Be a Barrier to Trial Participation
Cody HoltResearch presented during WCLC 2022 shows patient-centered summaries may help potential participants to better understand the benefits and risks of clinical trials. Read more
Get Up to Date on SCLC Brain Metastases, Neuroendocrine Tumors
Fred GebhartExperts evaluate available evidence comparing various strategies, including prophylactic cranial irradiation vs. surveillance, stereotactic radiosurgery vs. whole-brain radiotherapy, and more. Read more